Air Products And Chemicals (APD) Following Revenue Of US$12.6b Is The Undervaluation Story Still Intact
Air Products and Chemicals (APD) has drawn fresh attention after reporting annual revenue of US$12.6b alongside a net income loss of US$47.3m. This has prompted investors to reassess the industrial gases specialist.
Recent trading has been choppy, with Air Products and Chemicals’ share price down 5.68% over the past month and 3.27% over the last week. However, the 90-day share price return of 2.99% and year-to-date gain of 16.35% suggest longer-term momentum remains intact, alongside a 1-year total shareholder return of 2.18%.
Compare how Air Products and Chemicals stacks up against other industrials by scanning our curated list of list of solid balance sheet and fundamentals (23 results) for potential alternatives and complements to your watchlist.
Air Products and Chemicals has rebounded this year, yet still trades at a discount to both analyst targets and one intrinsic value estimate. Is most of the easy upside already behind the stock, or is investors’ patience still being underpriced?
Most Popular Narrative: 14.9% Undervalued
Against a last close of $291.43, the most followed narrative for Air Products and Chemicals pins fair value near $342, leaving a sizeable valuation gap on paper.
Heavy investments in large-scale hydrogen, blue/green ammonia, and carbon capture projects, supported by multi-decade power and supply agreements in growth regions (e.g., Middle East, Asia, U.S. Gulf Coast), are set to come online over the next several years, providing robust and stable earnings and supporting a trajectory of consistently higher operating margins.
Want to see what turns that project backlog into a higher price tag for Air Products and Chemicals? The narrative leans heavily on rising margins, faster top line expansion, and a future profit multiple that would usually belong to faster growing sectors. Curious which specific revenue path and profitability step change need to hold for that fair value to make sense?
Result: Fair Value of $342.42 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Air Products and Chemicals faces two swing factors that could challenge this upside story: prolonged helium softness and any major cost overruns or delays on large hydrogen or ammonia projects.
Find out about the key risks to this Air Products and Chemicals narrative.
Another View: Air Products and Chemicals Looks Expensive On Sales
There is a catch. On a sales based lens, Air Products and Chemicals trades on a P/S of 5.1x, which is richer than both the US Chemicals industry at 1.1x and a fair ratio of 2.4x that the market could move toward over time. Is this a high quality premium or valuation risk?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around Air Products and Chemicals can pull you in either direction, so move quickly, test the assumptions, and weigh both sides using the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Air Products and Chemicals?
If Air Products and Chemicals has you rethinking your watchlist, use this moment to refresh your broader opportunity set. A few focused screens can quickly surface companies that better match your risk and return preferences.
Use the Simply Wall St Screener to explore new angles before the crowd moves on.
- Target potential mispricings by reviewing a curated set of 32 high quality undervalued stocks that combine quality fundamentals with more modest expectations in the share price.
- Strengthen the defensive side of your portfolio by scanning a 11 resilient stocks with low risk scores that emphasizes steadier balance sheets and more predictable financial profiles.
- Explore a focused pool of 15 high quality undiscovered gems that have solid metrics but currently attract limited attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com